Kathryn S Nevel1,2, Natalie DiStefano3,2, Xuling Lin1,2, Anna Skakodub1,2, Shahiba Q Ogilvie3,4,2, Anne S Reiner5,2, Elena Pentsova1,3,2, Adrienne Boire1,3,6,2. 1. Department of Neurology, New York, New York. 2. Memorial Sloan Kettering Cancer Center, New York, New York. 3. Brain Tumor Center, New York, New York. 4. Department of Neurosurgery, New York, New York. 5. Department of Epidemiology and Biostatistics, New York, New York. 6. Human Oncology and Pathogenesis Program, New York, New York.
Abstract
BACKGROUND: Improvements in detection and molecular characterization of leptomeningeal metastasis from lung cancer (LC-LM) coupled with cerebrospinal fluid (CSF)-penetrating targeted therapies have altered disease management. A barrier to formal study of these therapies in LM is quantification of disease burden. Also, outcomes of patients with targetable mutations in LC-LM are not well defined. This study employs molecular and radiographic measures of LM disease burden and correlates these with outcome. METHODS: We reviewed charts of 171 patients with LC-LM treated at Memorial Sloan Kettering. A subset had MRI and CSF studies available. Radiographic involvement (n = 76) was scored by number of gadolinium-enhancing sites in 8 locations. CSF studies included cytopathology, circulating tumor cell (CTC) quantification (n = 16), and cell-free DNA (cfDNA) analysis (n = 21). Clinical outcomes were compared with Kaplan-Meier log-rank test and Cox proportional hazards methodologies. RESULTS: Median overall survival was 4.2 months (95% CI: 3.6-4.9); 84 patients (49%) harbored targetable mutations. Among bevacizumab-naïve patients with MRI and CSF cytology at time of LC-LM diagnosis, extent of radiographic involvement correlated with risk of death (hazard ratio [HR]: 1.16; 95% CI: 1.02-1.33; P = 0.03), as did CSF CTC (HR: 3.39, 95% CI: 1.01-11.37; P = 0.048) and CSF cfDNA concentration (HR: 2.58; 95% CI: 0.94-7.05; P = 0.06). Those without a targetable mutation were almost 50% more likely to die (HR: 1.49; 95% CI: 1.06-2.11; P = 0.02). CONCLUSIONS: Extent of radiographic involvement and quantification of CSF CTC and cfDNA show promise as prognostic indicators. These findings support molecular characterization and staging for clinical management, prognostication, and clinical trial stratification of LC-LM.
BACKGROUND: Improvements in detection and molecular characterization of leptomeningeal metastasis from lung cancer (LC-LM) coupled with cerebrospinal fluid (CSF)-penetrating targeted therapies have altered disease management. A barrier to formal study of these therapies in LM is quantification of disease burden. Also, outcomes of patients with targetable mutations in LC-LM are not well defined. This study employs molecular and radiographic measures of LM disease burden and correlates these with outcome. METHODS: We reviewed charts of 171 patients with LC-LM treated at Memorial Sloan Kettering. A subset had MRI and CSF studies available. Radiographic involvement (n = 76) was scored by number of gadolinium-enhancing sites in 8 locations. CSF studies included cytopathology, circulating tumor cell (CTC) quantification (n = 16), and cell-free DNA (cfDNA) analysis (n = 21). Clinical outcomes were compared with Kaplan-Meier log-rank test and Cox proportional hazards methodologies. RESULTS: Median overall survival was 4.2 months (95% CI: 3.6-4.9); 84 patients (49%) harbored targetable mutations. Among bevacizumab-naïve patients with MRI and CSF cytology at time of LC-LM diagnosis, extent of radiographic involvement correlated with risk of death (hazard ratio [HR]: 1.16; 95% CI: 1.02-1.33; P = 0.03), as did CSF CTC (HR: 3.39, 95% CI: 1.01-11.37; P = 0.048) and CSF cfDNA concentration (HR: 2.58; 95% CI: 0.94-7.05; P = 0.06). Those without a targetable mutation were almost 50% more likely to die (HR: 1.49; 95% CI: 1.06-2.11; P = 0.02). CONCLUSIONS: Extent of radiographic involvement and quantification of CSF CTC and cfDNA show promise as prognostic indicators. These findings support molecular characterization and staging for clinical management, prognostication, and clinical trial stratification of LC-LM.
Authors: Emilie Le Rhun; Patrick Devos; Thomas Boulanger; Marion Smits; Dieta Brandsma; Roberta Rudà; Julia Furtner; Johann-Martin Hempel; Tjeerd J Postma; Patrick Roth; Tom J Snijders; Frank Winkler; Sebastian Winklhofer; Antonella Castellano; Elke Hattingen; Jaume Capellades; Thierry Gorlia; Martin Van den Bent; Patrick Y Wen; Martin Bendszus; Michael Weller Journal: Neuro Oncol Date: 2019-05-06 Impact factor: 12.300
Authors: Christian Grommes; Geoffrey R Oxnard; Mark G Kris; Vincent A Miller; William Pao; Andrei I Holodny; Jennifer L Clarke; Andrew B Lassman Journal: Neuro Oncol Date: 2011-08-24 Impact factor: 12.300
Authors: Justine L Kuiper; Lizza E Hendriks; Anthonie J van der Wekken; Adrianus J de Langen; Idris Bahce; Erik Thunnissen; Daniëlle A M Heideman; Yvonne Berk; Ed J M Buijs; Ernst-Jan M Speel; Frans H Krouwels; Hans J M Smit; Harry J M Groen; Anne-Marie C Dingemans; Egbert F Smit Journal: Lung Cancer Date: 2015-06-06 Impact factor: 5.705
Authors: Marc Chamberlain; Larry Junck; Dieta Brandsma; Riccardo Soffietti; Roberta Rudà; Jeffrey Raizer; Willem Boogerd; Sophie Taillibert; Morris D Groves; Emilie Le Rhun; Julie Walker; Martin van den Bent; Patrick Y Wen; Kurt A Jaeckle Journal: Neuro Oncol Date: 2017-04-01 Impact factor: 12.300
Authors: Ulrich Herrlinger; Heike Förschler; Wilhelm Küker; Richard Meyermann; Michael Bamberg; Johannes Dichgans; Michael Weller Journal: J Neurol Sci Date: 2004-08-30 Impact factor: 3.181
Authors: Myung Han Hyun; Jae Sook Sung; Eun Joo Kang; Yoon Ji Choi; Kyong Hwa Park; Sang Won Shin; Sung Yong Lee; Yeul Hong Kim Journal: Oncotarget Date: 2017-10-10
Authors: Emilie Le Rhun; Patrick Devos; Sebastian Winklhofer; Hafida Lmalem; Dieta Brandsma; Priya Kumthekar; Antonella Castellano; Annette Compter; Frederic Dhermain; Enrico Franceschi; Peter Forsyth; Julia Furtner; Norbert Galldiks; Jaime Gállego Pérez-Larraya; Jens Gempt; Elke Hattingen; Johann Martin Hempel; Slavka Lukacova; Giuseppe Minniti; Barbara O'Brien; Tjeerd J Postma; Patrick Roth; Roberta Rudà; Niklas Schaefer; Nils O Schmidt; Tom J Snijders; Steffi Thust; Martin van den Bent; Anouk van der Hoorn; Guillaume Vogin; Marion Smits; Joerg C Tonn; Kurt A Jaeckle; Matthias Preusser; Michael Glantz; Patrick Y Wen; Martin Bendszus; Michael Weller Journal: Neuro Oncol Date: 2022-10-03 Impact factor: 13.029
Authors: Catherine A O'Connor; Jennifer S Park; Thomas Kaley; Brie Kezlarian; Marcia Edelweiss; T Jonathan Yang; Wungki Park; Diane Reidy; Anna M Varghese; Kenneth H Yu; Eileen M O'Reilly Journal: Pancreatology Date: 2021-02-06 Impact factor: 3.996
Authors: Rimas V Lukas; Jigisha P Thakkar; Massimo Cristofanilli; Sunandana Chandra; Jeffrey A Sosman; Jyoti D Patel; Priya Kumthekar; Roger Stupp; Maciej S Lesniak Journal: J Neurooncol Date: 2022-01-20 Impact factor: 4.130
Authors: Tejus A Bale; Soo-Ryum Yang; James P Solomon; Khedoudja Nafa; Sumit Middha; Jacklyn Casanova; Justyna Sadowska; Anna Skakodub; Hamza Ahmad; Helena A Yu; Greg J Riely; Mark G Kris; Sarat Chandarlapaty; Marc K Rosenblum; Igor Gavrilovic; Matthias A Karajannis; Elena Pentsova; Alexandra Miller; Adrienne Boire; Ingo Mellinghoff; Michael F Berger; Ahmet Zehir; Marc Ladanyi; Ryma Benayed; Maria E Arcila Journal: J Mol Diagn Date: 2021-03-27 Impact factor: 5.341
Authors: Maria Diaz; Priya Singh; Ivan S Kotchetkov; Anna Skakodub; Alicia Meng; Christel Tamer; Robert J Young; Anne S Reiner; Katherine S Panageas; Lakshmi V Ramanathan; Elena Pentsova Journal: J Neurooncol Date: 2022-02-03 Impact factor: 4.506